<DOC>
	<DOCNO>NCT00003022</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy treat patient leptomeningeal metastasis .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Leptomeningeal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Define clinical toxicity intrathecal iodine I 131 monoclonal antibody 3F8 ( I-3F8 ) patient GD2 positive leptomeningeal neoplasm . - Determine whether I-3F8 detect GD2 positive leptomeningeal tumor . - Measure cerebrospinal fluid ( CSF ) level serum pharmacokinetics I-3F8 patient . OUTLINE : This dose escalation study . Patients receive single injection intraventricular intrathecal iodine I 131 monoclonal antibody 3F8 . Patients without objective disease progression grade 3 4 toxicity 6 week first dose may receive second injection . Cohorts least 3 patient enter escalate dos I-3F8 . If grade 3 bad toxicity occur 1 3 patient give dose level , 3 additional patient accrue level . If 2 6 patient give dose level experience grade 3 bad toxicity , dose declare maximum tolerate dose ( MTD ) . Patients follow weekly 4 week . PROJECTED ACCRUAL : Approximately 3-30 patient accrue study 2-3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy express GD2 , include , limited : Medulloblastoma/primitive neuroectodermal tumor CNS Malignant glioma Neuroblastoma Retinoblastoma Ependymoma Sarcoma Melanoma Small cell lung carcinoma Other tumor type must GD2 expression confirm immunohistochemical stain Cerebrospinal fluid leptomeningeal disease refractory conventional therapy conventional therapy exist Prior measurable human antimouse monoclonal antibody titer allow PATIENT CHARACTERISTICS : Age : 3 Performance status : Not specify Life expectancy : At least 2 month Hematopoietic : Absolute neutrophil count great 1,000/mm^3 Platelet count great 50,000/mm^3 Hepatic : Bilirubin le 3 mg/dL Renal : Creatinine le 2 mg/dL Blood urea nitrogen le 30 mg/dL Other : May active malignancy outside central nervous system No obstructive hydrocephalus No CNS grade 3 4 toxicity consequence prior treatment No life threaten infection PRIOR CONCURRENT THERAPY : Biologic therapy : Prior monoclonal antibody treatment allow Chemotherapy : Prior chemotherapy allow Must recover hematopoietic neurologic side effect prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow At least 6 week since prior cranial spinal irradiation Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>retinoblastoma</keyword>
	<keyword>intraocular retinoblastoma</keyword>
	<keyword>extraocular retinoblastoma</keyword>
	<keyword>recurrent retinoblastoma</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>ciliary body choroid melanoma , small size</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood visual pathway glioma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>localize Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult supratentorial primitive neuroectodermal tumor ( PNET )</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>